Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2026
TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05563480 (A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma), which is not on this map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
TypeinterventionalSponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.Ran2022 to 2025Enrolled47ConditionsNasopharyngeal CarcinomaArmsTQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, TQB2618 injection, Penpulimab injection
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
28 authors.
Cheng Xu *Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0002-4503-6029
Si-Yang Wang *Cancer Center, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, P. R. China.ORCID 0000-0002-0248-1536
Man Nie *Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0001-6109-9268
Kun-Yu Yang *Department of Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.ORCID 0000-0002-2575-4736
Xin-Qiong Huang *Department of Radiation Oncology, Xiangya Hospital of Central South University, Changsha, P. R. China.ORCID 0009-0003-2928-9012
Song Qu *Cancer Center, Guangxi Medical University Cancer Hospital, Guangxi Cancer Institute, Guangxi Cancer Hospital, Nanning, P. R. China.ORCID 0000-0001-8186-1934
Hui ChenChia Tai Tian Qing Pharmaceutical Group Co., Ltd., Nanjing, P. R. China.ORCID 0009-0004-4434-817X
Liang-Fang ShenDepartment of Radiation Oncology, Xiangya Hospital of Central South University, Changsha, P. R. China.ORCID 0000-0002-7538-7188
Jing HuangDepartment of Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.ORCID 0000-0003-2232-3727
Fan ZhangCancer Center, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, P. R. China.ORCID 0009-0002-3545-2878
Ying-Peng PengCancer Center, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, P. R. China.ORCID 0000-0002-9665-8362
Liang-Liang ShiDepartment of Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.ORCID 0000-0001-6457-2890
Xiao-Hua HongDepartment of Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.ORCID 0000-0002-4356-7002
Zhan-Jie ZhangDepartment of Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.ORCID 0000-0003-0191-5715
Ling-Long TangDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0002-8561-1454
Ling GuoDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0001-7133-3951
Pu-Yun OuyangDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0002-6754-3910
Jian-Ming GaoDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0009-0002-3476-1679
Yan-Ping MaoDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0003-1027-071X
Ying HuangDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0002-8801-3660
Rui GuoDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0003-1683-0837
Li-Zhi LiuDepartment of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.ORCID 0000-0002-3977-0518
Li TianDepartment of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.ORCID 0000-0001-6891-8414
Hao-Jiang LiDepartment of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.ORCID 0000-0001-5854-3989
Ji-Bin LiClinical Trials Center, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0001-7632-3648
Jun MaDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0002-1137-9349
Yi XiaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0009-0003-1526-1043
Qing-Qing CaiDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.ORCID 0000-0001-5447-3282
Funding
Basic and Applied Basic Research Project of Science and Technology of Guangzhou City 2023A04J1786Changping Laboratory Project 2025C-12-04Guangdong Basic and Applied Basic Research Foundation 2024A1515011150Guangdong Basic and Applied Basic Research Foundation 2024A1515012975National Natural Science Foundation of China (NSFC) 81930072National Natural Science Foundation of China (NSFC) 82230001National Natural Science Foundation of China (NSFC) 82573549Tip-top Scientific and Technical Innovative Youth Talents of Guangdong Special Support Program TZ09B0046
6 · The paper itself
Abstract
purposeThe purpose of this study was to evaluate the efficacy and safety of dual immunotherapy blocking T-cell immunoglobulin and mucin domain-containing protein-3 (TIM-3) and programmed cell death protein-1 (PD-1) in recurrent/metastatic nasopharyngeal carcinoma. PATIENTS AND
methodsThe TQB2618 plus penpulimab (TP) cohort enrolled patients with progression on prior PD-1 or programmed cell death ligand-1 blockade to receive intravenous TP every 3 weeks. The TP combined with gemcitabine-cisplatin (TPGC) cohort enrolled treatment-naïve patients to receive TQB2618, penpulimab, gemcitabine, and cisplatin every 3 weeks for four to six cycles, followed by maintenance dual immunotherapy. Primary endpoints were dose-limiting toxicity (DLT) and objective response rate for the TP cohort and progression-free survival (PFS) for the TPGC cohort. This two-cohort trial is registered with ClinicalTrials.gov (NCT05563480).
resultsBetween November 2022 and October 2023, 17 patients were enrolled in the TP cohort and 30 in the TPGC cohort. No DLTs were observed. In the TP cohort, disease control was achieved in 10 (58.8%) of 17 patients, with no complete or partial responses; the median PFS was 1.6 months [95% confidence interval (CI), 0-3.2]. In the TPGC cohort, the objective response rate was 86.2%, including 4 (13.8%) complete responses. The median PFS was 10.8 months (95% CI, 9.6-16.4), with a 12-month rate of 40.9%; the median overall survival was unreached. Grade 3 to 4 treatment-related adverse events occurred in 2 (11.8%) patients in the TP cohort and 25 (83.3%) in the TPGC cohort, predominantly hematologic toxicities.
conclusionsTP combined with gemcitabine-cisplatin demonstrated encouraging antitumor activity and a manageable safety profile in treatment-naïve patients. However, the chemotherapy-free dual regimen showed limited efficacy in immunotherapy-refractory disease.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial. · full record | OpenQuestion